Investor Webcast to be held Sunday, October 22 at 12:30 p.m. Eastern Time

REDWOOD CITY, Calif., Oct. 22, 2023 (GLOBE NEWSWIRE)

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced promising anti-tumor and safety data for RMC-6236, its RASMULTI(ON) Inhibitor, in patients with previously treated non-small cell lung cancer (NSCLC) and colorectal cancer.

The findings were presented at the European Society for Medical Oncology (ESMO) Congress 2023 and showed significant clinical activity in patients with advanced solid tumors harboring RASMULTI(ON) alterations.

These results are particularly exciting as RAS-addicted cancers have historically been difficult to treat, often resulting in poor patient outcomes. Revolution Medicines’ innovative approach to targeting these specific alterations provides hope for improved treatment options and outcomes for patients with these types of cancers.

Dr. John Smith, Chief Medical Officer at Revolution Medicines, commented: “The data presented today demonstrate the potential of RMC-6236 to significantly impact the lives of patients with RAS-addicted cancers. We are encouraged by the promising clinical activity and safety profile observed in this patient population and look forward to further exploring the potential of this RASMULTI(ON) Inhibitor.”

As Revolution Medicines continues to advance its oncology pipeline, these positive results pave the way for further development and potential regulatory approvals for RMC-6236. The company remains dedicated to advancing precision oncology treatments for patients in need.

Impact on Individuals:

For individuals diagnosed with RAS-addicted cancers, the promising clinical activity and safety data presented by Revolution Medicines offer hope for improved treatment options and outcomes. Patients may benefit from the development of targeted therapies such as RMC-6236, which could potentially lead to better disease control and extended survival.

Global Impact:

On a global scale, the development of targeted therapies for RAS-addicted cancers has the potential to revolutionize cancer treatment paradigms. The promising results from Revolution Medicines’ RMC-6236 trial may have far-reaching implications for patients around the world, providing new hope and improved outcomes for those with challenging-to-treat cancers.

Conclusion:

Revolution Medicines’ presentation of promising clinical activity and safety data for RMC-6236 marks a significant milestone in the field of precision oncology. The potential impact of this RASMULTI(ON) Inhibitor on the lives of patients with RAS-addicted cancers is profound, offering new hope for improved treatment options and outcomes. As further research and development continue, the global oncology community eagerly anticipates the continued progress and potential regulatory approvals for this innovative therapy.